cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14938038
title: Supplementary Material for: Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants

description: <b><i>Introduction:</i></b> Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder characterized by progressive deterioration of motor neurons. Assessment of the size/geographic distribution of the ALS population, including ALS with genetic origin, is needed to understand the burden of the disease and the need for clinical intervention and therapy. <b><i>Objectives:</i></b> The main objective of this study was to estimate the number of prevalent and incident ALS cases overall and superoxide dismutase 1 (SOD1) and chromosome 9 open reading frame 72 (C9orf72) ALS in 22 countries across Europe (Belgium, France, Germany, Ireland, Italy, Netherlands, Norway, Russia, Spain, Sweden, and UK), North America (USA and Canada), Latin America (Argentina, Brazil, Colombia, Mexico, and Uruguay), and Asia (China, Japan, South Korea, and Taiwan). <b><i>Methods:</i></b> A comprehensive literature search was conducted to identify population-based studies reporting ALS prevalence and/or incidence rates. Pooled prevalence and incidence rates were obtained using a meta-analysis approach at the country and regional geographic level. A country-level pooled estimate was used when ≥2 studies were available per country and geographic regional pooled estimates were used otherwise. The proportion of cases with a SOD1 or C9orf72 mutation among sporadic (sALS) and familial (fALS) cases were obtained from a previous systematic review and meta-analysis. <b><i>Results:</i></b> Pooled prevalence rates (per 100,000 persons) and incidence rates (per 100,000 person-years) were 6.22 and 2.31 for Europe, 5.20 and 2.35 for North America, 3.41 and 1.25 for Latin America, 3.01 and 0.93 for Asian countries excluding Japan, and 7.96 and 1.76 for Japan, respectively. Significant heterogeneity in reported incidence and prevalence was observed within and between countries/geographic regions. The estimated number of 2020 ALS cases across the 22 countries is 121,028 prevalent and 41,128 incident cases. The total estimated number of prevalent SOD1 cases is 2,876 cases, of which, 1,342 (47%) were fALS and 1,534 (53%) were sALS, and the number of incident SOD1 cases is 946 (434 [46%] fALS and 512 [54%] sALS). The total estimated number of prevalent C9orf72 cases is 4,545 (1,198 [26%] fALS, 3,347 [74%] sALS), and the number of incident C9orf72 cases is 1,706 (450 [26%] fALS and 1,256 [74%] sALS). <b><i>Discussion:</i></b> The estimated number of patients with SOD1 and C9orf72 ALS suggests that although the proportions of SOD1 and C9orf72 are higher among those with fALS, the majority of SOD1 and C9orf72 ALS cases may be found among those with sALS (about 53 and 74%, respectively). These results suggest that classification of fALS based on reported family history does not capture the full picture of ALS of genetic origin.
DOI: 10.35110/24f156b3-1240-414b-b643-cdc82c484772
title: plot of the berambadi watershed in 2019-2020

description: Vector file representing the Berambadi watershed located in southern India, Karnataka State.
DOI: 10.5281/zenodo.5084443
title: Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Systemic corticosteroids for the treatment of COVID-19.

description: Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: Systemic corticosteroids for the treatment of COVID-19.
description: funded by the Federal Ministry of Education and Research, Germany (NaFoUniMedCovid19, funding number: 01KX2021; part of the project "CEOSys"
DOI: 10.5281/zenodo.5084449
title: SciExpeM - 10.5281/zenodo.5084449

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084448
title: SciExpeM - 10.5281/zenodo.5084449

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084451
title: SciExpeM - 10.5281/zenodo.5084451

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084450
title: SciExpeM - 10.5281/zenodo.5084451

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084455
title: SciExpeM - 10.5281/zenodo.5084455

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084454
title: SciExpeM - 10.5281/zenodo.5084455

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084457
title: SciExpeM - 10.5281/zenodo.5084457

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084456
title: SciExpeM - 10.5281/zenodo.5084457

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084459
title: SciExpeM - 10.5281/zenodo.5084459

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084458
title: SciExpeM - 10.5281/zenodo.5084459

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084467
title: SciExpeM - 10.5281/zenodo.5084467

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084466
title: SciExpeM - 10.5281/zenodo.5084467

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084469
title: SciExpeM - 10.5281/zenodo.5084469

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084468
title: SciExpeM - 10.5281/zenodo.5084469

description: Alzueta, Maria U; Bilbao, Rafael; Glarborg, Peter - Combustion And Flame, 2001, (127), 2234-2251
DOI: 10.5281/zenodo.5084471
title: SciExpeM - 10.5281/zenodo.5084471

description: Colom-Díaz, J.M.; Leciñena, M.; Peláez, A.; Abián, M.; Millera, Á.; Bilbao, R.; Alzueta, M.U. - Fuel, 2020, (262), 116484
DOI: 10.5281/zenodo.5084470
title: SciExpeM - 10.5281/zenodo.5084471

description: Colom-Díaz, J.M.; Leciñena, M.; Peláez, A.; Abián, M.; Millera, Á.; Bilbao, R.; Alzueta, M.U. - Fuel, 2020, (262), 116484
DOI: 10.6084/m9.figshare.12271292.v14
title: Arrival catalog of coronal mass ejections observed with STEREO Heliospheric Imagers (HELCATS ARRCAT 2.0)

description: ARRIVAL CATALOGUE 2.0 <br>In this ARRival CATalog (ARRCAT), the arrivals of solar coronal mass ejections that were tracked in the STEREO heliospheric imagers in the HELCATS project are calculated.<br>ARRCAT lists modeled arrivals of CMEs at various spacecraft and planets, between April 2007 - January 2021, based on the HIGeoCAT catalog of CMEs established at RAL Space, UK (R. A. Harrison, J. A. Davies, D. Barnes). <br>This is version 2.0, released 2020-May-13, updated 2020-Feb-11.<br>https://doi.org/10.6084/m9.figshare.12271292<br>It is based on this HIGeoCAT version: https://www.helcats-fp7.eu/catalogues/data/HCME_WP3_V06.vot using the SSEF30 model.<br>The catalog is available as python pandas dataframe (pickle), python numpy arrays (pickle, as recarray and structured array),npy (numpy, no pickle), json, csv, xlsx, txt, hdf5, html at https://helioforecast.space/arrcathttps://www.helcats-fp7.eu<br>Number of events in ARRCAT: 1620Targets: Earth_L1, STEREO-A, STEREO-B, Solar Orbiter, Parker Solar Probe (PSP), Bepi Colombo, Ulysses, Venus, Mercury, Mars.<br>For further description, see header file.<br>source code: arrcat.ipynb inhttps://github.com/cmoestl/heliocats<br>Rules: If results are produced with this catalog for peer-reviewed scientific publications,please contact christian.moestl@oeaw.ac.at for co-authorships.<br>
DOI: 10.6084/m9.figshare.5928610
title: Disclosing respiratory co-infections: a broad-range panel assay for avian respiratory pathogens on a nanofluidic PCR platform

description: Respiratory syndromes (RS) are among the most significant pathological conditions in edible birds and are caused by complex coactions of pathogens and environmental factors. In poultry, low pathogenic avian influenza A viruses, metapneumoviruses, infectious bronchitis virus, infectious laryngotracheitis virus, <i>Mycoplasma</i> spp. <i>Escherichia coli</i> and/or <i>Ornithobacterium rhinotracheale</i> in turkeys are considered as key co-infectious agents of RS. <i>Aspergillus</i> sp., <i>Pasteurella multocida, Avibacterium paragallinarum</i> or <i>Chlamydia psittaci</i> may also be involved in respiratory outbreaks. An innovative quantitative PCR method, based on a nanofluidic technology, has the ability to screen up to 96 samples with 96 pathogen-specific PCR primers, at the same time, in one run of real-time quantitative PCR. This platform was used for the screening of avian respiratory pathogens: 15 respiratory agents, including viruses, bacteria and fungi potentially associated with respiratory infections of poultry, were targeted. Primers were designed and validated for SYBR green real-time quantitative PCR and subsequently validated on the Biomark high throughput PCR nanofluidic platform (Fluidigm©, San Francisco, CA, USA). As a clinical assessment, tracheal swabs were sampled from turkeys showing RS and submitted to this panel assay. Beside systematic detection of <i>E. coli</i>, avian metapneumovirus, <i>Mycoplasma gallisepticum</i> and <i>Mycoplasma synoviae</i> were frequently detected, with distinctive co-infection patterns between French and Moroccan flocks. This proof-of-concept study illustrates the potential of such panel assays for unveiling respiratory co-infection profiles in poultry.
DOI: 10.6084/m9.figshare.5982241.v1
title: Assessment of <i>Mycoplasma gallisepticum</i> vaccine efficacy in a co-infection challenge model with QX-like infectious bronchitis virus

description: <i>Mycoplasma gallisepticum</i> (MG) is the primary cause of chronic respiratory disease in poultry. We investigated the protective efficacy of the live-attenuated ts-11 and 6/85 MG vaccines against a local MG strain and, in order to enhance signs and mimic a typical field situation, we co-infected birds with a virulent strain of QX-like infectious bronchitis virus (IBV). Both vaccines showed similar ability to protect infected chickens from clinical signs, although ts-11 performed slightly better. Despite the lower protection against clinical disease, 6/85-vaccinated birds had significantly (<i>P</i> ≤ 0.05) lower tracheal lesion scores and mucosal thickness at day 28 post-vaccination (7 days post-challenge [dpc] with MG, 2 dpc IBV) and day 31 post-vaccination (10 dpc MG challenge, 5 dpc IBV) compared to ts-11 vaccinated birds, but these difference was not significant at day 33 (12 dpc MG, 7 dpc IBV). Pathogen infection and replication was assessed by qPCR, and the 6/85 vaccine produced a more significant (<i>P</i> ≤ 0.05) reduction in MG replication in the lungs, kidneys and livers but enhanced late replication in bursae and caecal tonsils. In contrast, the ts-11 vaccine had a more pronounced reductive effect on replication in tracheas, air sacs, bursae and heart at days 28 and 31, yet increased replication in lungs. Interestingly, both vaccines provided non-specific protection against IBV challenge. The co-challenge model provided useful data on vaccine efficacy, especially on days 31 and 33, and tracheas, lungs, air sacs, kidneys, liver and caecal tonsils were the best organs to assess.
DOI: 10.6084/m9.figshare.5982241
title: Assessment of <i>Mycoplasma gallisepticum</i> vaccine efficacy in a co-infection challenge model with QX-like infectious bronchitis virus

description: <i>Mycoplasma gallisepticum</i> (MG) is the primary cause of chronic respiratory disease in poultry. We investigated the protective efficacy of the live-attenuated ts-11 and 6/85 MG vaccines against a local MG strain and, in order to enhance signs and mimic a typical field situation, we co-infected birds with a virulent strain of QX-like infectious bronchitis virus (IBV). Both vaccines showed similar ability to protect infected chickens from clinical signs, although ts-11 performed slightly better. Despite the lower protection against clinical disease, 6/85-vaccinated birds had significantly (<i>P</i> ≤ 0.05) lower tracheal lesion scores and mucosal thickness at day 28 post-vaccination (7 days post-challenge [dpc] with MG, 2 dpc IBV) and day 31 post-vaccination (10 dpc MG challenge, 5 dpc IBV) compared to ts-11 vaccinated birds, but these difference was not significant at day 33 (12 dpc MG, 7 dpc IBV). Pathogen infection and replication was assessed by qPCR, and the 6/85 vaccine produced a more significant (<i>P</i> ≤ 0.05) reduction in MG replication in the lungs, kidneys and livers but enhanced late replication in bursae and caecal tonsils. In contrast, the ts-11 vaccine had a more pronounced reductive effect on replication in tracheas, air sacs, bursae and heart at days 28 and 31, yet increased replication in lungs. Interestingly, both vaccines provided non-specific protection against IBV challenge. The co-challenge model provided useful data on vaccine efficacy, especially on days 31 and 33, and tracheas, lungs, air sacs, kidneys, liver and caecal tonsils were the best organs to assess.
DOI: 10.6084/m9.figshare.5928610.v3
title: Disclosing respiratory co-infections: a broad-range panel assay for avian respiratory pathogens on a nanofluidic PCR platform

description: Respiratory syndromes (RS) are among the most significant pathological conditions in edible birds and are caused by complex coactions of pathogens and environmental factors. In poultry, low pathogenic avian influenza A viruses, metapneumoviruses, infectious bronchitis virus, infectious laryngotracheitis virus, <i>Mycoplasma</i> spp. <i>Escherichia coli</i> and/or <i>Ornithobacterium rhinotracheale</i> in turkeys are considered as key co-infectious agents of RS. <i>Aspergillus</i> sp., <i>Pasteurella multocida, Avibacterium paragallinarum</i> or <i>Chlamydia psittaci</i> may also be involved in respiratory outbreaks. An innovative quantitative PCR method, based on a nanofluidic technology, has the ability to screen up to 96 samples with 96 pathogen-specific PCR primers, at the same time, in one run of real-time quantitative PCR. This platform was used for the screening of avian respiratory pathogens: 15 respiratory agents, including viruses, bacteria and fungi potentially associated with respiratory infections of poultry, were targeted. Primers were designed and validated for SYBR green real-time quantitative PCR and subsequently validated on the Biomark high throughput PCR nanofluidic platform (Fluidigm©, San Francisco, CA, USA). As a clinical assessment, tracheal swabs were sampled from turkeys showing RS and submitted to this panel assay. Beside systematic detection of <i>E. coli</i>, avian metapneumovirus, <i>Mycoplasma gallisepticum</i> and <i>Mycoplasma synoviae</i> were frequently detected, with distinctive co-infection patterns between French and Moroccan flocks. This proof-of-concept study illustrates the potential of such panel assays for unveiling respiratory co-infection profiles in poultry.
DOI: 10.6084/m9.figshare.5928610.v2
title: Disclosing respiratory co-infections: a broad-range panel assay for avian respiratory pathogens on a nanofluidic PCR platform

description: Respiratory syndromes (RS) are among the most significant pathological conditions in edible birds and are caused by complex coactions of pathogens and environmental factors. In poultry, low pathogenic avian influenza A viruses, metapneumoviruses, infectious bronchitis virus, infectious laryngotracheitis virus, <i>Mycoplasma</i> spp. <i>Escherichia coli</i> and/or <i>Ornithobacterium rhinotracheale</i> in turkeys are considered as key co-infectious agents of RS. <i>Aspergillus</i> sp., <i>Pasteurella multocida, Avibacterium paragallinarum</i> or <i>Chlamydia psittaci</i> may also be involved in respiratory outbreaks. An innovative quantitative PCR method, based on a nanofluidic technology, has the ability to screen up to 96 samples with 96 pathogen-specific PCR primers, at the same time, in one run of real-time quantitative PCR. This platform was used for the screening of avian respiratory pathogens: 15 respiratory agents, including viruses, bacteria and fungi potentially associated with respiratory infections of poultry, were targeted. Primers were designed and validated for SYBR green real-time quantitative PCR and subsequently validated on the Biomark high throughput PCR nanofluidic platform (Fluidigm©, San Francisco, CA, USA). As a clinical assessment, tracheal swabs were sampled from turkeys showing RS and submitted to this panel assay. Beside systematic detection of <i>E. coli</i>, avian metapneumovirus, <i>Mycoplasma gallisepticum</i> and <i>Mycoplasma synoviae</i> were frequently detected, with distinctive co-infection patterns between French and Moroccan flocks. This proof-of-concept study illustrates the potential of such panel assays for unveiling respiratory co-infection profiles in poultry.
DOI: 10.6084/m9.figshare.6046982.v1
title: Co-infection of turkeys with <i>Escherichia coli</i> (O78) and H6N1 avian influenza virus

description: Respiratory diseases are responsible for major economic losses in poultry farms. While in most cases a single pathogen is not alone responsible for the clinical outcome, the impact of co-infections is not well known, especially in turkeys. The purpose of this study was to assess the possible synergism between <i>Escherichia coli</i> (O78) and low pathogenic avian influenza virus (LPAIV, H6N1), in the turkey model. Four-week-old commercial turkeys were inoculated with either H6N1, O78 or both agents simultaneously or three days apart. We have established an experimental infection model of turkeys using aerosolization that better mimics field infections. Birds were observed clinically and swabbed on a daily basis. Necropsies were performed at 4 and 14 days post single or dual inoculation and followed by histological and immunohistochemical analyses. Combined LPAIV/<i>E. coli</i> infections resulted in more severe clinical signs, were associated with higher mortality and respiratory organ lesions (mucous or fibrinous exudative material in lungs and air sacs), in comparison with the groups given single infections (<i>P</i> E. coli inoculation (none or three days) did not have a significant effect on the outcome of the dual infection and disease although slightly greater (<i>P</i> &gt; 0.05) respiratory signs were observed in turkeys of the <i>E. coli</i> followed by H6N1 inoculated group. Microscopic lesions and immunohistochemical staining supported clinical and macroscopic findings. Efficient virus and bacteria replication was observed in all inoculated groups. <i>E. coli</i> and H6N1 thus exercise an additive or synergistic pathogenic effect in the reproduction of respiratory disease.
DOI: 10.25502/xdcc-bw27/d
title: Using moth capture in pheromone traps and damage incidence as decision tools for pesticide intervention (Season 2) 

description: Testing different levels of moth capture in pheromone traps and damage incidence as decision tools for pesticide intervention.
DOI: 10.5517/ccdc.csd.cc27s26b
title: CCDC 2078711: Experimental Crystal Structure Determination

description: Related Article: Nigam P. Rath, Stephen M. Holmes|2021|Polyhedron|206|115324|doi:10.1016/j.poly.2021.115324
DOI: 10.5517/ccdc.csd.cc27sg2l
title: CCDC 2079079: Experimental Crystal Structure Determination

description: Related Article: Jun Fan, Ming-Chung Yang, Thomas J. N. Hooper, Ming-Der Su, Cheuk-Wai So|2021|Organometallics|40|1848|doi:10.1021/acs.organomet.1c00108
DOI: 10.5517/ccdc.csd.cc26vt0x
title: CCDC 2051549: Experimental Crystal Structure Determination

description: Related Article: Jun Fan, Ming-Chung Yang, Thomas J. N. Hooper, Ming-Der Su, Cheuk-Wai So|2021|Organometallics|40|1848|doi:10.1021/acs.organomet.1c00108
DOI: 10.5517/ccdc.csd.cc27tjtf
title: CCDC 2080125: Experimental Crystal Structure Determination

description: Related Article: Peter M. Chapple, Ghanem Hamdoun, Thierry Roisnel, Jean-François Carpentier, Hassan Oulyadi, Yann Sarazin|2021|Dalton Trans.|50|9021|doi:10.1039/D1DT01615F
DOI: 10.5517/ccdc.csd.cc27tjvg
title: CCDC 2080126: Experimental Crystal Structure Determination

description: Related Article: Peter M. Chapple, Ghanem Hamdoun, Thierry Roisnel, Jean-François Carpentier, Hassan Oulyadi, Yann Sarazin|2021|Dalton Trans.|50|9021|doi:10.1039/D1DT01615F
DOI: 10.5517/ccdc.csd.cc27tjxj
title: CCDC 2080128: Experimental Crystal Structure Determination

description: Related Article: Peter M. Chapple, Ghanem Hamdoun, Thierry Roisnel, Jean-François Carpentier, Hassan Oulyadi, Yann Sarazin|2021|Dalton Trans.|50|9021|doi:10.1039/D1DT01615F
DOI: 10.5517/ccdc.csd.cc23l12v
title: CCDC 1953746: Experimental Crystal Structure Determination

description: Related Article: Cheng-gang Jiang, Yan-fang Yuan, Xiao-yu Meng, Ke-Ke Zhou, Gui-lin Zhuang, Bao Li, Tianle Zhang|2021|Dalton Trans.|50|9016|doi:10.1039/D1DT01527C
DOI: 10.5517/ccdc.csd.cc23l11t
title: CCDC 1953745: Experimental Crystal Structure Determination

description: Related Article: Cheng-gang Jiang, Yan-fang Yuan, Xiao-yu Meng, Ke-Ke Zhou, Gui-lin Zhuang, Bao Li, Tianle Zhang|2021|Dalton Trans.|50|9016|doi:10.1039/D1DT01527C